Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
The offering and sale of the Notes will be made pursuant to our effective automatic shelf registration statement on Form S-3, including our base prospectus, filed with the Securities and Exchange Commission (the “SEC”) on February 7, 2025. The offering of …